Growth hormone insensitivity syndrome
MONDO:0015892Growth hormone insensitivity syndrome (GHIS) is a group of diseases characterized by marked short stature associated with normal or elevated growth hormone (GH) concentrations, which fail to respond to exogenous GH administration. GHIS comprises growth delay due to IGF-1 deficiency, growth delay due to IGF-1 resistance, Laron syndrome, short stature due to STAT5b deficiency and primary acid-labile subunit (ALS) deficiency.
Also known as: GHIS, Growth hormone insensitivity syndromes, short stature due to a defect in growth hormone receptor or post-receptor pathway
6 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease
Disease control Recruiting nowThis study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammati…
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
New antibody drug aims to ease double vision and bulging eyes in thyroid disease
Disease control Recruiting nowThis study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 is an antibody that blocks a protein involved in the disease. The goal is to see if it improves eye symptoms …
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:04 UTC
-
New combo therapy aims to tame thyroid eye disease
Disease control Recruiting nowThis study tests a two-step treatment for people with moderate-to-severe thyroid eye disease (TAO) that is still active. First, patients receive high-dose steroids, then a newer drug called tetuzumab (IBI311) that blocks a growth factor receptor. The goal is to reduce bulging eye…
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:42 UTC
-
Global registry tracks safety of growth drug in kids
Knowledge-focused Recruiting nowThis global registry follows 500 children and teens with severe primary IGF-1 deficiency who are taking or will take Increlex® (mecasermin). The goal is to monitor long-term safety and side effects over at least 5 years after treatment ends. It is an observational study, meaning …
Sponsor: Esteve Pharmaceuticals, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC